NCT05475210 - 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 18, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

March 30, 2025

Conditions

Neuroendocrine Tumors

Interventions

DRUG

177Lu-DOTA-EB-TATE

Peptide Receptor Radionucleotide Therapy ( PRRT) using 177Lu-DOTA-EB-TATE with a defined number of cycles will be administered.

OTHER

Amino Acid Solution

The Amino acid solution to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.

Trial Locations (1)

RECRUITING

Memorial Sloan Kettering Cancer Center, New York